Omid Farokhzad, MD
Omid Farokhzad, MD, is an associate professor at Harvard Medical School (HMS), a physician-scientist in the Department of Anesthesiology at Brigham and Women’s Hospital (BWH), a research affiliate in the Harvard-MIT Division of Health Sciences and Technology (HST), and a faculty member of the Brigham Research Institute Cancer Research Center at BWH. He is also a member of the Dana Farber/Harvard Cancer Center Programs in Prostate Cancer and Cancer Cell Biology. He received graduate and medical degrees from the Boston University School of Medicine, followed by post-graduate clinical and post-doctoral research training, respectively, at BWH/HMS and MIT in the laboratory of Professor Robert Langer.
Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH, which he established in 2004. The Farokhzad lab focuses on the development of therapeutic nanoparticle technologies. Most notably, Dr. Farokhzad pioneered the high-throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored approximately 100 papers and holds more then 125 issued/pending U.S. and international patents. The technologies that Dr. Farokhzad has developed with collaborators at HMS, DFCI, Cornell and MIT have formed the basis for 1) a new class of targeted nanoparticles for treatment of important human diseases including cancer and cardiovascular disease; 2) a new class of synthetic nanoparticle vaccines for prophylactic and therapeutic applications and 3) a new class of integrative combination nanomedicines for synergistic treatment of cancers, inflammation/pain, and infectious diseases. These technologies formed the foundational platform for the launch of three biotechnology companies: BIND Therapeutics (NASDAQ: BIND), Selecta Biosciences, Blend Therapeutics, which are translating the aforementioned academic innovations toward commercialization and societal impact.
Dr. Farokhzad is a member of the College of the Fellows of the American Institute of Medical and Biological Engineering. He was among the recipients of the Nano50 award from NASA Nanotech Briefs, presented to highly innovative people and design ideas that have the potential to revolutionize nanotechnology. In addition, he was among the 15 recipients across all industries to receive the All Star Distinguished Achievement Award from the Mass High Tech Journal for his contributions to the life sciences industry. In 2012, he received an Ernst & Young Entrepreneur of the Year award. In 2013, the Boston Globe selected him among the top innovators in Massachusetts, and the Boston Business Journal selected him among the Health Care Champions for his innovations.Back to Commercialization Council